Back to search results

Observational Study for Early Cancer Detection

This observational study, called "Strategic Targeting for Optimal Prevention of Cancer," aims to understand the benefits of using genetic testing to assess your risk for hereditary cancers. Researchers will collect data from individuals aged 65 or older who have already undergone genetic testing (using a buccal swab, or cheek swab) for hereditary cancer based on their doctor's recommendation. The genetic tests look for changes in genes like ATM, BRCA1, BRCA2, and TP53, which are linked to an increased risk of certain cancers. The main goal is to see how this genetic information helps doctors guide preventative measures and potentially lead to earlier detection and treatment of cancer. This study plans to include 120,000 participants.

Study design
This is an observational study, meaning researchers will collect data from existing medical records rather than giving you a new treatment. It aims to include 120,000 participants.
What's involved
You would not undergo any new procedures or tests as part of this study. Your existing medical information, including results from hereditary cancer genetic testing ordered by your doctor, would be collected.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints for this study, which involve genomic cancer screening, are measured at 120 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03897374

Strategic Targeting for Optimal Prevention of Cancer

Recruiting
Not specifiedAges 65+Observational
ClinLogic LLC
~120,000 participants
Updated 2026-03-19 on ClinicalTrials.gov
What's tested:Genetic Testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Genomic cancer screen
Measured over 120 Days
+1 more outcome measured

Conditions

Early Detection of Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Who to contact

C David, MBA
[email protected]
7174671201
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

individuals, ages 65 years or older;
must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity;
hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations.
study subject has or had cancer
study subject has at least one family member with cirrent or past cancer

Exclusion

Study subjects will be excluded from the study if any of the following criteria apply: • study subject is currently hospitalized or incarcerated;
study subject is unable to provide an accurate history due to mental incapacity
study subject is currently abusing illicit and/or prescription drugs;

What this trial measures

  • Genomic cancer screen120 Days

    A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation.

  • Genomic cancer screen120 Days

    A genotype known to be a predisposition for cancer.